Breckenridge Recalls Megestrol Acetate Oral Suspension for Stability Failures
Breckenridge Pharmaceutical is recalling Megestrol Acetate Oral Suspension due to out-of-specification particle size results during stability testing.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Breckenridge Pharmaceutical, Inc. is recalling specific lots of Megestrol Acetate Oral Suspension, USP 625 mg/5mL, 150 mL bottles. The product is distributed nationwide within the United States and is manufactured by Pharmaceutics International Inc.
The recall was initiated because the product failed stability specifications. Specifically, out-of-specification results were obtained for particle size distribution during stability testing. The affected lots are 5599.008A, 5599.009A, 5599.010A (Exp. 04/2019), 5599.012A, 5599.013A (Exp. 11/2019), and 5599.014A (Exp. 01/2020).
The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences. Patients and healthcare providers should check their inventory for the affected lot numbers and contact the recalling firm for further instructions.
The recalled product
- Product
- Megestrol Acetate Oral Suspension, USP 625 mg/5mL, 150 mL bottle, Rx only, Distributed by: Breckenridge Pharmaceutical, Inc. Boca Raton, FL 33487, Manufactured by: Pharmaceutics International Inc. Hunt Valley, MD 21031
- Manufacturer
- Breckenridge Pharmaceutical, Inc.
- Category
- Drug — Oral Suspension
- Hazard
- Affected units
- 9,193
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot #: 5599.008A
- 5599.009A
- 5599.010A
- Exp. 04/2019
- 5599.012A
- 5599.013A
- Exp. 11/2019
- 5599.014A
- Exp. 01/2020
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Breckenridge Pharmaceutical, Inc.
See all →- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- HighDuloxetine delayed-release capsules recalled over a nitrosamine impurity above FDA limits
FDA (Drugs) · 2025-12-10
- HighIntelliVue MX550 patient monitors recalled over an alarm activation issue
FDA (Drugs) · 2025-12-10
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24